Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) should contact The Gross Law Firm about pending Class Action - UNCY

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [2][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from March 29, 2024, to June 27, 2025 [2]. - Allegations include overstating Unicycive's readiness to meet FDA manufacturing compliance and the regulatory prospects of its oxylanthanum carbonate new drug application [2]. Group 2: Shareholder Actions - Shareholders who purchased UNCY shares during the class period are encouraged to register for the class action and can seek lead plaintiff status by the deadline of October 14, 2025 [3]. - Registration allows shareholders to receive updates through portfolio monitoring software regarding the case's progress [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [4].